Hepatocellular Carcinoma Clinical Trials

60 studies are recruiting for hepatocellular carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Houston, Texas 14 San Antonio, Texas 9 Pittsburgh, Pennsylvania 8 Los Angeles, California 7 Cleveland, Ohio 6 Dallas, Texas 6 New York, New York 6 Orange, California 6 Philadelphia, Pennsylvania 6 St Louis, Missouri 6 La Jolla, California 5 Seattle, Washington 5 Tampa, Florida 5 Duarte, California 4 Fairfax, Virginia 4 Grand Rapids, Michigan 4 Milwaukee, Wisconsin 4 Ann Arbor, Michigan 3 Aurora, Colorado 3 Baltimore, Maryland 3 Birmingham, Alabama 3 Chicago, Illinois 3 Denver, Colorado 3 Detroit, Michigan 3 Jacksonville, Florida 3 Oklahoma City, Oklahoma 3 San Francisco, California 3 The Bronx, New York 3

Studies, page 3

  1. Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

    This study evaluates barriers to early detection of liver cancer.

    Stage
    Not phased
    Ages
    18 and older
    Site
    USC / Norris Comprehensive Cancer Center, Los Angeles, California
    Run by
    University of Southern California

    See if you can join NCT07312162 on ClinicalTrials.gov

  2. Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

    The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
    Locations
    2 in total
    Run by
    Anwaar Saeed

    See if you can join NCT03539822 on ClinicalTrials.gov

  3. A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

    This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose …

    Stage
    Not phased
    Ages
    18 and older
    Site
    UC San Diego Moores Cancer Center, La Jolla, California
    Locations
    2 in total
    Run by
    Replimune, Inc.

    See if you can join NCT06887348 on ClinicalTrials.gov

  4. Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

    This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged popul…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UT Health San Antonio, San Antonio, Texas
    Run by
    The University of Texas Health Science Center at San Antonio

    See if you can join NCT06526104 on ClinicalTrials.gov

  5. Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

    This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
    Locations
    3 in total
    Run by
    Anwaar Saeed

    See if you can join NCT06698250 on ClinicalTrials.gov

  6. Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

    The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly c…

    Stage
    Phase 1
    Ages
    Up to 21
    Site
    Houston Methodist Hospital, Houston, Texas
    Run by
    Baylor College of Medicine

    See if you can join NCT06198296 on ClinicalTrials.gov

  7. Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

    This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia, Sofia,
    Locations
    32 in total
    Run by
    Can-Fite BioPharma

    See if you can join NCT05201404 on ClinicalTrials.gov

  8. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Curebase, San Francisco, California
    Run by
    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov

  9. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    3 in total
    Run by
    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov

  10. Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

    The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Tennessee Medical Center, Knoxville, Tennessee
    Run by
    University of Tennessee

    See if you can join NCT03686709 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.